A new international study has found that everolimus may help successfully shrink agiomyolipomas (AMLs) in patients with tuberous sclerosis complex (TSC). John Schieszer reports in today’s Medical Minute that this agent may substantially reduce the size of kidney tumors in a substantial number in patients with TSC.